Drugs Made In America Acquisition Corp. (DMAAU) Cash & Equivalents (2024 - 2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Cash & Equivalents came in at $6137.0 in Q4 2025, up 354.26% YoY from $1351.0 in Q4 2024, and up 755.93% on a QoQ basis from $717.0 in Q3 2025.
Drugs Made In America Acquisition Corp. (DMAAU) Cash & Equivalents (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 2 years of Cash & Equivalents data on file, last reported at $6137.0 in Q4 2025.
- Quarterly Cash & Equivalents rose 354.26% year-over-year to $6137.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6137.0 (up 354.26% YoY) and the FY2025 annual result came in at $6137.0, up 354.26% from the prior year.
- Cash & Equivalents climbed to $6137.0 in Q4 2025, from $717.0 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $6137.0 in Q4 2025 to a low of $717.0 in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6,137.00 |
| Sep 30, 2025 | 717.00 |
| Jun 30, 2025 | 822.00 |
| Mar 31, 2025 | 923.00 |
| Dec 31, 2024 | 1,351.00 |